The evaluation of effectiveness of dT vaccine on immune response to HB vaccine in non responder dialysis patients

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT138812093454N1

Enrollment

Registered

2010-04-24

Start date

2009-03-15

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

End Stage Renal Disease. ESRD

Interventions

Intervention 1: dT vaccine injection simultaneously with first dose of HBV vaccine. Intervention 2: HBV vaccine (40µgr) injection at 0,1,6 month.

Treatment - Drugs

dT vaccine injection simultaneously with first dose of HBV vaccine

HBV vaccine (40µgr) injection at 0,1,6 month

Eligibility

Sex/Gender

All

Age

18 Years to 149 Years

Inclusion criteria

Inclusion criteria: Inclusion:1)age>=18yr,2)hemodialysis and peritoneal dialysis patients,3)comleted at least 3 dose HBV vaccine schedule and had HBS Ab <10 Exclusion:1)no compliance,2)renal transplant

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
HBS Ab titer. Timepoint: 1-2 m and 6 month after completing vaccination. Method of measurement: ELISA.	—

Secondary

Measure	Time frame
--------. Timepoint: -----. Method of measurement: ------.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr.Shahrzad Shahidi

Isfahan University Of Medical Sciences

shahidi@med.mui.ac.ir+98 31 1663 6858

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026